Junshi Bio hands Fosun Wanbang China commercial rights to roconkibart

Edited by Robert McTiernan··2 min read

China-based biopharma Shanghai Junshi Biosciences Co., Ltd. (HKEX: 01877) has granted Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. exclusive development, registration, and commercialization rights to roconkibart (JS005), its proprietary anti-IL-17A monoclonal antibody, across the Greater China region. The deal, executed on June 30, 2026, carries an upfront payment of RMB 215 million (around USD 32 million) and potential milestones of up to RMB 1,125 million (USD 166 million), and transfers near-term commercialization responsibility for a molecule with an accepted NDA to a partner with an established autoimmune disease sales infrastructure.

The agreement arrives as roconkibart’s New Drug Application for moderate to severe plaque psoriasis was accepted by China’s National Medical Products Administration in December 2025. The timing of the Junshi Bio partnership means Fosun Wanbang assumes commercial execution risk and responsibility at the most capital-intensive stage of the asset’s lifecycle, while Junshi Bio retains royalty and milestone upside without bearing the full cost of building a dedicated sales force in the autoimmune segment across Greater China.

The manufacturing license granted under the agreement is co-exclusive rather than exclusive, a distinction that preserves Junshi Bio’s ability to manufacture roconkibart independently or to engage additional manufacturing partners outside the licensed territory. This structural choice limits Fosun Wanbang’s control over the supply chain while ensuring it retains sufficient manufacturing rights to support commercial operations within Greater China.

The AllSci BriefSystematic R&D and deal news. Daily.

The IL-17A inhibitor class is well-established, with secukinumab (Cosentyx) from Novartis and ixekizumab (Taltz) from Eli Lilly holding dominant positions globally in psoriasis and ankylosing spondylitis. Both molecules are approved and commercially active in China. Bimekizumab (Bimzelx) from UCB, which targets both IL-17A and IL-17F, represents a more recent entrant with a differentiated dual-cytokine mechanism. Roconkibart’s dual binding to the IL-17A homodimer and the IL-17A/IL-17F heterodimer positions it mechanistically closer to bimekizumab than to secukinumab or ixekizumab, though whether this translates into differentiated clinical outcomes has not been established in head-to-head data.

The Phase III psoriasis data cited in the announcement — a PASI 90 response rate of 91% at week 16 and a PASI 100 response rate of 65% at week 52 in the 150 mg dosing group — are competitive with published data for approved agents, though cross-trial comparisons carry well-recognized methodological limitations.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/